Magdalena Biosciences, Inc.
Joint venture founded to discover and develop pharmaceutical-grade botanical drug candidates for neuropsychiatric indications. The company holds an exclusive license to a characterized library of medicinal plants and extracts and focuses on accelerating development of IND-enabled botanical medicines (claimed pathway from plant collection to initiation of human proof-of-concept studies in 12–24 months). Initial therapeutic focus includes treatments for executive dysfunction in ADHD and cognitive deficits in schizophrenia.
Industries
N/A
Products
Botanical drug candidate for cognitive deficits in schizophrenia (first botanical candidate)
Pharmaceutical-grade botanical drug candidate advanced for treatment of cognitive deficits associated with schizophrenia; part of the company's IND-enabled pipeline.
Pipeline of IND-enabled botanical drug candidates (ADHD, schizophrenia, anxiety, depression)
Multiple botanical candidates in development intended to address executive dysfunction in ADHD and cognitive/positive/negative symptoms in schizophrenia, as well as anxiety and depression.
Botanical drug candidate for cognitive deficits in schizophrenia (first botanical candidate)
Pharmaceutical-grade botanical drug candidate advanced for treatment of cognitive deficits associated with schizophrenia; part of the company's IND-enabled pipeline.
Pipeline of IND-enabled botanical drug candidates (ADHD, schizophrenia, anxiety, depression)
Multiple botanical candidates in development intended to address executive dysfunction in ADHD and cognitive/positive/negative symptoms in schizophrenia, as well as anxiety and depression.
Services
Botanical drug discovery and development
Discovery and development of pharmaceutical-grade botanical drug candidates from a curated medicinal plant library for neuropsychiatric indications.
Preclinical evaluation and pharmacology
Conducting preclinical studies to evaluate psychoactive activity and mechanisms of action for plant-derived candidates.
Regulatory development for botanical drugs
Preparation of IND-enabling data packages and alignment with FDA Botanical Drug Guidance toward potential clinical trials and regulatory submissions.
Ethnobotanical sourcing and access/benefit-sharing facilitation
Field collection coordination, sustainable sourcing practices and establishment of access and benefit-sharing agreements for research materials.
Botanical drug discovery and development
Discovery and development of pharmaceutical-grade botanical drug candidates from a curated medicinal plant library for neuropsychiatric indications.
Preclinical evaluation and pharmacology
Conducting preclinical studies to evaluate psychoactive activity and mechanisms of action for plant-derived candidates.
Regulatory development for botanical drugs
Preparation of IND-enabling data packages and alignment with FDA Botanical Drug Guidance toward potential clinical trials and regulatory submissions.
Ethnobotanical sourcing and access/benefit-sharing facilitation
Field collection coordination, sustainable sourcing practices and establishment of access and benefit-sharing agreements for research materials.
Expertise Areas
- Botanical drug development
- Ethnobotany and sustainable sourcing
- Preclinical pharmacology for CNS/psychiatric indications
- Clinical proof-of-concept initiation and trial planning
Key Technologies
- Phytochemical extraction and purification
- Botanical standardization and characterization
- Preclinical animal and in vitro pharmacology models (CNS/psychiatric)
- Clinical proof-of-concept trial execution